Passage Bio, Inc. – NASDAQ:PASG
Passage Bio stock price today
$6.53
+5.87
+893.91%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Passage Bio stock price monthly change
-30.11%
month
Passage Bio stock price quarterly change
-30.11%
quarter
Passage Bio stock price yearly change
-30.28%
year
Passage Bio key metrics
Market Cap | 39.53M |
Enterprise value | 49.11M |
P/E | -0.48 |
EV/Sales | N/A |
EV/EBITDA | -0.37 |
Price/Sales | N/A |
Price/Book | 0.28 |
PEG ratio | -0.01 |
EPS | -1.54 |
Revenue | N/A |
EBITDA | -88.94M |
Income | -84.43M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePassage Bio stock price history
Passage Bio stock forecast
Passage Bio financial statements
| Jun 2023 | 0 | -23.85M | |
|---|---|---|---|
| Sep 2023 | 0 | -27.11M | |
| Dec 2023 | 5.91M | -16.75M | -283.46% |
| Mar 2024 | 0 | -16.71M |
| Dec 2023 | 5.91M | -16.75M | -283.46% |
|---|---|---|---|
| Mar 2024 | 0 | -16.71M | |
| Oct 2025 | 0 | -10.13M | |
| Dec 2025 | 0 | -10.13M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 193696000 | 43.28M | 22.35% |
|---|---|---|---|
| Sep 2023 | 169256000 | 42.98M | 25.39% |
| Dec 2023 | 150545000 | 39.26M | 26.08% |
| Mar 2024 | 140531000 | 35.64M | 25.37% |
| Jun 2023 | -17.13M | 13.96M | 89K |
|---|---|---|---|
| Sep 2023 | -19.16M | 22.45M | 0 |
| Dec 2023 | -19.51M | 7.6M | 46K |
| Mar 2024 | -18.92M | 25.25M | 8.74M |
Passage Bio alternative data
| Aug 2023 | 85 |
|---|---|
| Sep 2023 | 85 |
| Oct 2023 | 85 |
| Nov 2023 | 85 |
| Dec 2023 | 85 |
| Jan 2024 | 85 |
| Feb 2024 | 85 |
| Mar 2024 | 58 |
| Apr 2024 | 58 |
| May 2024 | 58 |
| Jun 2024 | 58 |
| Jul 2024 | 58 |
Passage Bio other data
69.79%
-5.85%
of PASG is owned by hedge funds
62
-16
37.95M
-3.09M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 42298 |
| Feb 2024 | 0 | 3108 |
| Sep 2024 | 0 | 239431 |
| Nov 2024 | 456353 | 0 |
| Dec 2024 | 0 | 389700 |
| Quarter | Transcript |
|---|---|
| Q4 2022 6 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 10 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 6 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 16 May 2022 | Q1 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Bruce A. Goldsmith M.B.A., Ph.D. (1966) Chief Executive Officer, Pres & Director | $756,920 |
-
What's the price of Passage Bio stock today?
One share of Passage Bio stock can currently be purchased for approximately $6.53.
-
When is Passage Bio's next earnings date?
Unfortunately, Passage Bio's (PASG) next earnings date is currently unknown.
-
Does Passage Bio pay dividends?
No, Passage Bio does not pay dividends.
-
How much money does Passage Bio make?
Passage Bio has a market capitalization of 39.53M.
-
What is Passage Bio's stock symbol?
Passage Bio, Inc. is traded on the NASDAQ under the ticker symbol "PASG".
-
What is Passage Bio's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Passage Bio?
Shares of Passage Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Passage Bio's key executives?
Passage Bio's management team includes the following people:
- Dr. Bruce A. Goldsmith M.B.A., Ph.D. Chief Executive Officer, Pres & Director(age: 59, pay: $756,920)
-
How many employees does Passage Bio have?
As Jul 2024, Passage Bio employs 58 workers.
-
When Passage Bio went public?
Passage Bio, Inc. is publicly traded company for more then 5 years since IPO on 28 Feb 2020.
-
What is Passage Bio's official website?
The official website for Passage Bio is passagebio.com.
-
Where are Passage Bio's headquarters?
Passage Bio is headquartered at One Commerce Square, Philadelphia, PA.
-
How can i contact Passage Bio?
Passage Bio's mailing address is One Commerce Square, Philadelphia, PA and company can be reached via phone at +267 8660311.
Passage Bio company profile:
Passage Bio, Inc.
passagebio.comExchange:
NASDAQ
Full time employees:
58
Industry:
Biotechnology
Sector:
Healthcare
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
One Commerce Square
Philadelphia, PA 19103
Philadelphia, PA 19103
CIK: 0001787297
ISIN: US7027121000
CUSIP: 702712100
